S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 12.88 CHF -0.16% Market Closed
Market Cap: 174m CHF

Wall Street
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

Lowest
Price Target
30.3 CHF
135% Upside
Average
Price Target
30.6 CHF
138% Upside
Highest
Price Target
31.5 CHF
145% Upside
Santhera Pharmaceuticals Holding AG Competitors:
Price Targets
KURN
Kuros Biosciences AG
28% Upside
BNTX
BioNTech SE
48% Upside
6160
Beigene Ltd
36% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
48% Upside
OXB
Oxford BioMedica PLC
24% Upside
ARWR
Arrowhead Pharmaceuticals Inc
10% Downside
ALNY
Alnylam Pharmaceuticals Inc
24% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
36% Upside

Revenue
Forecast

Revenue Estimate
Santhera Pharmaceuticals Holding AG

For the last 13 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 21%. The projected CAGR for the next 3 years is 60%.

21%
Past Growth
60%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat

Net Income
Forecast

Net Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SANN's stock price target?
Price Target
30.6 CHF

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

What is Santhera Pharmaceuticals Holding AG's Revenue forecast?
Projected CAGR
60%

For the last 13 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 21%. The projected CAGR for the next 3 years is 60%.

Back to Top